1
|
Niknam M, Liaghat T, Zarghami M, Akrami M, Shahnematollahi SM, Ahmadipour A, Moazzen F, Soltanabadi S. Ghrelin and ghrelin/total cholesterol ratio as independent predictors for coronary artery disease: a systematic review and meta-analysis. J Investig Med 2022; 70:759-765. [PMID: 35042826 DOI: 10.1136/jim-2021-002100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/07/2021] [Indexed: 11/04/2022]
Abstract
The present meta-analysis aimed to summarize the available data regarding the circulating levels of ghrelin in patients with cardiovascular diseases (CVDs). A comprehensive search was performed in electronic databases including PubMed, Scopus, EMBASE, and Web of Science up to January 20, 2021. Since the circulating levels of ghrelin were measured in different units across the included studies, they were expressed as the standardized mean difference (SMD) and 95% CI (summary effect size). A random-effects model comprising the DerSimonian and Laird method was used to pool SMDs. Sixteen articles (20 studies) comprised of 1087 cases and 437 controls were included. The pooled results showed that there were no significant differences between cases and controls in terms of ghrelin levels (SMD=-0.61, 95% CI -1.38 to 0.16; p=0.120; I2=96.9%, p<0.001). The ghrelin concentrations in the CAD stratum were significantly lower than in controls, whereas they increased in other disease strata. New combined biomarkers demonstrated a significant decrease in the SMD of the ghrelin/total cholesterol (TC) ratio (-1.02; 95% CI -1.74 to -0.29, p=0.000; I2=94.5%). However, no significant differences were found in the SMD of the ghrelin/high-density lipoprotein cholesterol ratio, ghrelin/low-density lipoprotein cholesterol ratio, and ghrelin/triglyceride (TG) ratio in cases with CVDs compared with the control group. Ghrelin was associated with CAD; therefore, it may be considered a biomarker for distinguishing between patients with and without CAD. Furthermore, the ghrelin/TC ratio could be proposed as a diagnostic marker for CVD.
Collapse
Affiliation(s)
- Maryam Niknam
- Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Taraneh Liaghat
- Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Mehrdad Zarghami
- Cardiology Department, Fasa University of Medical Science, Fasa, Iran
| | - Mehdi Akrami
- Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| | | | - Ahmad Ahmadipour
- Student Research Committee, Zahedan University of Medical Sciences, Zahedan, Iran
| | - Fatemeh Moazzen
- Department of Hematology, Bushehr University of Medical Sciences, Bushehr, Iran
| | - Sahar Soltanabadi
- Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| |
Collapse
|
2
|
Sales da Silva E, Ferreira PM, Castro CH, Pacheco LF, Graziani D, Pontes CNR, Bessa ADSMD, Fernandes E, Naves LM, Ribeiro LCDS, Mendonça MM, Gomes RM, Pedrino GR, Ferreira RN, Xavier CH. Brain and kidney GHS-R1a underexpression is associated with changes in renal function and hemodynamics during neurogenic hypertension. Mol Cell Endocrinol 2020; 518:110984. [PMID: 32814069 DOI: 10.1016/j.mce.2020.110984] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2019] [Revised: 08/07/2020] [Accepted: 08/07/2020] [Indexed: 10/23/2022]
Abstract
Ghrelin is a peptide hormone whose effects are mediated by the growth hormone secretagogue receptor subtype 1a (GHS-R1a), mainly expressed in the brain but also in kidneys. The hypothesis herein raised is that GHS-R1a would be player in the renal contribution to the neurogenic hypertension pathophysiology. To investigate GHS-R1a role on renal function and hemodynamics, we used Wistar (WT) and spontaneously hypertensive rats (SHR). First, we assessed the effect of systemically injected vehicle, ghrelin, GHS-R1a antagonist PF04628935, ghrelin plus PF04628935 or GHS-R1a synthetic agonist MK-677 in WT and SHR rats housed in metabolic cages (24 h). Blood and urine samples were also analyzed. Then, we assessed the GHS-R1a contribution to the control of renal vasomotion and hemodynamics in WT and SHR. Finally, we assessed the GHS-R1a levels in brain areas, aorta, renal artery, renal cortex and medulla of WT and SHR rats using western blot. We found that ghrelin and MK-677 changed osmolarity parameters of SHR, in a GHS-R1a-dependent manner. GHS-R1a antagonism reduced the urinary Na+ and K+ and creatinine clearance in WT but not in SHR. Ghrelin reduced arterial pressure and increased renal artery conductance in SHR. GHS-R1a protein levels were decreased in the kidney and brain areas of SHR when compared to WT. Therefore, GHS-R1a role in the control of renal function and hemodynamics during neurogenic hypertension seem to be different, and this may be related to brain and kidney GHS-R1a downregulation.
Collapse
Affiliation(s)
- Elder Sales da Silva
- Systems Neurobiology Laboratory, Department of Physiology, Institute of Biological Sciences, Room 203, Federal University of Goiás, Goiânia, GO, 74690-900, Brazil.
| | - Patrícia Maria Ferreira
- Systems Neurobiology Laboratory, Department of Physiology, Institute of Biological Sciences, Room 203, Federal University of Goiás, Goiânia, GO, 74690-900, Brazil.
| | - Carlos Henrique Castro
- Systems Neurobiology Laboratory, Department of Physiology, Institute of Biological Sciences, Room 203, Federal University of Goiás, Goiânia, GO, 74690-900, Brazil.
| | - Lilian Fernanda Pacheco
- Systems Neurobiology Laboratory, Department of Physiology, Institute of Biological Sciences, Room 203, Federal University of Goiás, Goiânia, GO, 74690-900, Brazil.
| | - Daniel Graziani
- Systems Neurobiology Laboratory, Department of Physiology, Institute of Biological Sciences, Room 203, Federal University of Goiás, Goiânia, GO, 74690-900, Brazil.
| | - Carolina Nobre Ribeiro Pontes
- Systems Neurobiology Laboratory, Department of Physiology, Institute of Biological Sciences, Room 203, Federal University of Goiás, Goiânia, GO, 74690-900, Brazil.
| | - Amanda de Sá Martins de Bessa
- Systems Neurobiology Laboratory, Department of Physiology, Institute of Biological Sciences, Room 203, Federal University of Goiás, Goiânia, GO, 74690-900, Brazil.
| | - Erika Fernandes
- Systems Neurobiology Laboratory, Department of Physiology, Institute of Biological Sciences, Room 203, Federal University of Goiás, Goiânia, GO, 74690-900, Brazil.
| | - Lara Marques Naves
- Systems Neurobiology Laboratory, Department of Physiology, Institute of Biological Sciences, Room 203, Federal University of Goiás, Goiânia, GO, 74690-900, Brazil.
| | - Larissa Cristina Dos Santos Ribeiro
- Systems Neurobiology Laboratory, Department of Physiology, Institute of Biological Sciences, Room 203, Federal University of Goiás, Goiânia, GO, 74690-900, Brazil.
| | - Michelle Mendanha Mendonça
- Systems Neurobiology Laboratory, Department of Physiology, Institute of Biological Sciences, Room 203, Federal University of Goiás, Goiânia, GO, 74690-900, Brazil.
| | - Rodrigo Mello Gomes
- Systems Neurobiology Laboratory, Department of Physiology, Institute of Biological Sciences, Room 203, Federal University of Goiás, Goiânia, GO, 74690-900, Brazil.
| | - Gustavo Rodrigues Pedrino
- Systems Neurobiology Laboratory, Department of Physiology, Institute of Biological Sciences, Room 203, Federal University of Goiás, Goiânia, GO, 74690-900, Brazil.
| | - Reginaldo Nassar Ferreira
- Systems Neurobiology Laboratory, Department of Physiology, Institute of Biological Sciences, Room 203, Federal University of Goiás, Goiânia, GO, 74690-900, Brazil.
| | - Carlos Henrique Xavier
- Systems Neurobiology Laboratory, Department of Physiology, Institute of Biological Sciences, Room 203, Federal University of Goiás, Goiânia, GO, 74690-900, Brazil.
| |
Collapse
|
3
|
Pearson JT, Shirai M, Sukumaran V, Du CK, Tsuchimochi H, Sonobe T, Waddingham MT, Katare R, Schwenke DO. Ghrelin and vascular protection. VASCULAR BIOLOGY 2019; 1:H97-H102. [PMID: 32923960 PMCID: PMC7439925 DOI: 10.1530/vb-19-0024] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/11/2019] [Accepted: 09/05/2019] [Indexed: 12/11/2022]
Abstract
Ghrelin is a small peptide with important roles in the regulation of appetite, gut motility, glucose homeostasis as well as cardiovascular protection. This review highlights the role that acyl ghrelin plays in maintaining normal endothelial function by maintaining the balance of vasodilator-vasoconstrictor factors, inhibiting inflammatory cytokine production and immune cell recruitment to sites of vascular injury and by promoting angiogenesis.
Collapse
Affiliation(s)
- James T Pearson
- Department of Cardiac Physiology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan.,Department of Physiology and Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia
| | - Mikiyasu Shirai
- Department of Cardiac Physiology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan
| | - Vijayakumar Sukumaran
- Department of Cardiac Physiology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan
| | - Cheng-Kun Du
- Department of Cardiac Physiology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan
| | - Hirotsugu Tsuchimochi
- Department of Cardiac Physiology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan
| | - Takashi Sonobe
- Department of Cardiac Physiology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan
| | - Mark T Waddingham
- Department of Cardiac Physiology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan
| | - Rajesh Katare
- Department of Physiology, HeartOtago, School of Biomedical Sciences University of Otago, Dunedin, New Zealand
| | - Daryl O Schwenke
- Department of Physiology, HeartOtago, School of Biomedical Sciences University of Otago, Dunedin, New Zealand
| |
Collapse
|
4
|
Pearson JT, Collie N, Lamberts RR, Inagaki T, Yoshimoto M, Umetani K, Davis P, Wilkins G, Jones PP, Shirai M, Schwenke DO. Ghrelin Preserves Ischemia-Induced Vasodilation of Male Rat Coronary Vessels Following β-Adrenergic Receptor Blockade. Endocrinology 2018; 159:1763-1773. [PMID: 29325034 DOI: 10.1210/en.2017-03070] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/26/2017] [Accepted: 12/20/2017] [Indexed: 12/24/2022]
Abstract
Acute myocardial infarction (MI) triggers an adverse increase in cardiac sympathetic nerve activity (SNA). Whereas β-adrenergic receptor (β-AR) blockers are routinely used for the management of MI, they may also counter β-AR-mediated vasodilation of coronary vessels. We have reported that ghrelin prevents sympathetic activation following MI. Whether ghrelin modulates coronary vascular tone following MI, either through the modulation of SNA or directly as a vasoactive mediator, has never been addressed. We used synchrotron microangiography to image coronary perfusion and vessel internal diameter (ID) in anesthetized Sprague-Dawley rats, before and then again 30 minutes after induction of an MI (left coronary artery ligation). Rats were injected with either saline or ghrelin (150 µg/kg, subcutaneously), immediately following the MI or sham surgery. Coronary angiograms were also recorded following β-AR blockade (propranolol, 2 mg/kg, intravenously). Finally, wire myography was used to assess the effect of ghrelin on vascular tone in isolated human internal mammary arteries (IMAs). Acute MI enhanced coronary perfusion to nonischemicregions through dilation of small arterioles (ID 50 to 250 µm) and microvessel recruitment, irrespective of ghrelin treatment. In ghrelin-treated rats, β-AR blockade did not alter the ischemia-induced vasodilation, yet in saline-treated rats, β-AR blockade abolished the vasodilation of small arterioles. Finally, ghrelin caused a dose-dependent vasodilation of IMA rings (preconstricted with phenylephrine). In summary, this study highlights ghrelin as a promising adjunct therapy that can be used in combination with routine β-AR blockade treatment for preserving coronary blood flow and cardiac performance in patients who suffer an acute MI.
Collapse
Affiliation(s)
- James T Pearson
- Department of Cardiac Physiology, National Cerebral and Cardiovascular Center Research Institute, Suita, Osaka, Japan
| | - Nicola Collie
- Department of Physiology, School of Biomedical Sciences, HeartOtago University of Otago, Dunedin, New Zealand
| | - Regis R Lamberts
- Department of Physiology, School of Biomedical Sciences, HeartOtago University of Otago, Dunedin, New Zealand
| | - Tadakatsu Inagaki
- Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Suita, Osaka, Japan
| | - Misa Yoshimoto
- Department of Health Sciences, Nara Women's University, Nara, Japan
| | - Keiji Umetani
- Japan Synchrotron Radiation Research Institute, Hyogo, Japan
| | - Philip Davis
- Department of Cardiothoracic Surgery, HeartOtago, University of Otago, Dunedin, New Zealand
| | - Gerard Wilkins
- Department of Medicine Surgery, HeartOtago, University of Otago, Dunedin, New Zealand
| | - Pete P Jones
- Department of Physiology, School of Biomedical Sciences, HeartOtago University of Otago, Dunedin, New Zealand
| | - Mikiyasu Shirai
- Department of Advanced Medical Research for Pulmonary Hypertension, National Cerebral and Cardiovascular Center Research Institute, Suita, Osaka, Japan
| | - Daryl O Schwenke
- Department of Physiology, School of Biomedical Sciences, HeartOtago University of Otago, Dunedin, New Zealand
| |
Collapse
|
5
|
Sax B, Merkely B, Túri K, Nagy A, Ahres A, Hartyánszky I, Hüttl T, Szabolcs Z, Cseh K, Kékesi V. Characterization of pericardial and plasma ghrelin levels in patients with ischemic and non-ischemic heart disease. ACTA ACUST UNITED AC 2013; 186:131-6. [PMID: 23994275 DOI: 10.1016/j.regpep.2013.08.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2012] [Revised: 08/09/2013] [Accepted: 08/12/2013] [Indexed: 10/26/2022]
Abstract
Ghrelin is an endocrine regulatory peptide with multiple functions including cardioprotective effects. It is produced in various tissues among others in the myocardium. Pericardial fluid has been proven to be a biologically active compartment of the heart that communicates with the myocardial interstitium. Thus, pericardial level of certain agents may reflect their concentration in the myocardium well. In our study we measured acylated (active) and total (acylated and non-acylated) pericardial and plasma ghrelin levels of patients with ischemic and non-ischemic heart disease. Pericardial fluid and plasma samples were obtained from patients with coronary artery disease (ISCH, n=54) or valvular heart disease (VHD, n=41) undergoing cardiac surgery. Acylated pericardial ghrelin concentrations were found to be significantly higher in patients with ischemic heart disease (ISCH vs. VHD, 32±3 vs. 16±2pg/ml, p<0.01), whereas plasma levels of the peptide showed no difference between patient groups. Pericardial-to-plasma ratio, an index abolishing systemic effects on local ghrelin level was also significantly higher in ISCH group for both acylated and total ghrelin. Plasma total ghrelin showed negative correlation to BMI, plasma insulin and insulin resistance index HOMA-A. Pericardial acylated and total ghrelin concentrations were negatively correlated with posterior wall thickness (R=-0.31, p<0.05 and R=-0.35, p<0.01, respectively). Plasma insulin concentration and HOMA-A showed significant negative correlation with pericardial ghrelin levels. In conclusion, increased pericardial active ghrelin content and higher pericardial-to-plasma ghrelin ratio were found in ischemic heart disease as compared to non-ischemic patients suggesting an increased ghrelin production of the chronically ischemic myocardium. According to our results, pericardial ghrelin content is negatively influenced by left ventricular hypertrophy and insulin resistance.
Collapse
Affiliation(s)
- Balazs Sax
- Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Growth hormone secretagogues protect mouse cardiomyocytes from in vitro ischemia/reperfusion injury through regulation of intracellular calcium. PLoS One 2012; 7:e35265. [PMID: 22493744 PMCID: PMC3320867 DOI: 10.1371/journal.pone.0035265] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2011] [Accepted: 03/14/2012] [Indexed: 01/08/2023] Open
Abstract
Background Ischemic heart disease is a leading cause of mortality. To study this disease, ischemia/reperfusion (I/R) models are widely used to mimic the process of transient blockage and subsequent recovery of cardiac coronary blood supply. We aimed to determine whether the presence of the growth hormone secretagogues, ghrelin and hexarelin, would protect/improve the function of heart from I/R injury and to examine the underlying mechanisms. Methodology/Principal Findings Isolated hearts from adult male mice underwent 20 min global ischemia and 30 min reperfusion using a Langendorff apparatus. Ghrelin (10 nM) or hexarelin (1 nM) was introduced into the perfusion system either 10 min before or after ischemia, termed pre- and post-treatments. In freshly isolated cardiomyocytes from these hearts, single cell shortening, intracellular calcium ([Ca2+]i) transients and caffeine-releasable sarcoplasmic reticulum (SR) Ca2+ were measured. In addition, RT-PCR and Western blots were used to examine the expression level of GHS receptor type 1a (GHS-R1a), and phosphorylated phospholamban (p-PLB), respectively. Ghrelin and hexarelin pre- or post-treatments prevented the significant reduction in the cell shortening, [Ca2+]i transient amplitude and caffeine-releasable SR Ca2+ content after I/R through recovery of p-PLB. GHS-R1a antagonists, [D-Lys3]-GHRP-6 (200 nM) and BIM28163 (100 nM), completely blocked the effects of GHS on both cell shortening and [Ca2+]i transients. Conclusion/Significance Through activation of GHS-R1a, ghrelin and hexarelin produced a positive inotropic effect on ischemic cardiomyocytes and protected them from I/R injury probably by protecting or recovering p-PLB (and therefore SR Ca2+ content) to allow the maintenance or recovery of normal cardiac contractility. These observations provide supporting evidence for the potential therapeutic application of ghrelin and hexarelin in patients with cardiac I/R injury.
Collapse
|